INSIDER SESSION
LC/MS strategies for advanced modalities: ADC, AOC, multidomain and RNA therapeutics
Learn practical approaches for measuring all components of your molecule from scientific experts at BioAgilytix in this 45-minute webinar and Q&A.
This webinar highlights LC/MS-based strategies for the detection of novel drug modalities to support accurate, reliable, and fit-for-purpose PK analysis.
What will you learn?
Liquid chromatography–mass spectrometry (LC–MS) is a powerful platform for pharmacokinetic (PK) assessment across diverse therapeutic modalities, offering high specificity through detection of signature protein sequences and reduced susceptibility to matrix interference. For complex modalities—including antibody–drug conjugates (ADCs), antibody–oligonucleotide conjugates (AOCs), multimeric proteins and RNA therapeutics—LC–MS enables simultaneous measurement of multiple drug species, reduced reliance on critical reagents, and robust, regulatory-compliant analyses. This webinar will highlight LC–MS-based strategies for the detection of novel drug modalities to support accurate, reliable and fit-for-purpose PK analysis
Who may this interest?
-
Translational biologists
-
Clinical pharmacologists
-
Clinical operations
-
Bioanalytical scientists
-
LC–MS analytical chemists
Our experts will discuss lessons learned from their experiences and offer insight into the multiple stages of specific assays including critical reagents, regulatory standards, assay formats and timelines.
- Lynn Kamen, PhD: Scientific Officer, Executive Director, BioAgilytix
- Dave Beyerlein: Global LC/MS Lead, Vice President and General Manager, BioAgilytix
- Shashank Gorityala: Associate Director, BioAgilytix
- Ben Nie: Scientific Operations, BioAgilytix
In association with:
Share this Resource
